Physician profile

Robert E Wear

Pulmonary Disease · Omaha, NE

NPI 1285716423

$1,024.97

in general payments reported to CMS, 2019-2025

18 companies · $405 in 2025

The $405 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$546.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $188.58 2019-2025 Nucala
Insmed, INC. $151.39 2019-2025 Brinsupri, Arikayce
Grifols USA, LLC $118.89 2021-2025 Prolastin-C Liquid
Ethicon INC. $115.16 2020
Astrazeneca Pharmaceuticals Lp $79.05 2021-2025 Fasenra
Amgen INC. $60.52 2024-2025 Tezspire
Electromed, INC. $59.37 2024 Smartvest
Genentech USA, INC. $53.63 2019-2021
Jazz Pharmaceuticals INC. $39.74 2021-2023
Sunovion Pharmaceuticals INC. $22.69 2019
Boston Scientific Corporation $21.12 2025 Watchman Flx
Medtronic, INC. $20.49 2025 Illumisite
Philips North America LLC $18.19 2023
Pfizer INC. $16.13 2025
Takeda Pharmaceuticals U.S.A., INC. $15.75 2023 Glassia
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Hospira, INC. $15.50 2025
Teva Pharmaceuticals USA, INC. $15.00 2020
Novartis Pharmaceuticals Corporation $13.77 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert E Wear

$1,024.97

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $405 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/194577/robert-e-wear

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.